Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Notes Payables (2023 - 2024)

Historic Notes Payables for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $11.2 million.

  • Zhengye Biotechnology Holding's Notes Payables changed N/A to $11.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.2 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2024, which is 831.93% down from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Notes Payables of $11.2 million as of Q2 2025.
  • In the past 5 years, Zhengye Biotechnology Holding's Notes Payables registered a high of $11.2 million during Q2 2025, and its lowest value of $10.4 million during Q4 2024.
  • Its 3-year average for Notes Payables is $10.9 million, with a median of $11.1 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Zhengye Biotechnology Holding's Notes Payables was 656.28% (2024), while the steepest drop was 656.28% (2024).
  • Zhengye Biotechnology Holding's Notes Payables (Quarter) stood at $11.1 million in 2023, then dropped by 6.56% to $10.4 million in 2024, then increased by 7.87% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q2 2025, $10.4 million for Q4 2024, and $11.1 million during Q4 2023.